Plant Name: Myrsine capitellata
Taxonomic Information:
Plant ID: NPO10011
Plant Latin Name: Myrsine capitellata
Taxonomy Genus: Myrsine
Taxonomy Family: Primulaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
589068-1
Used in Medicines:
Country/Region:
China; IndiaTraditional Medicine System:
Indian Folk; TCMGeographical Distribution:
India; Nepal; China; Myanmar
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| ACHE; | |
| MET; AXL; FLT3; CDK1; MAPK1; PIM1; KDR; IGF1R; AURKB; CSNK2A1; | |
| CA12; CA7; CA4; | |
| ESR2; | |
| ALOX5; TYR; | |
| ALOX12; HSD17B1; HSD17B10; NOX4; HSD17B2; POLB; | |
| MMP12; | |
| AHR; HIF1A; | |
| L3MBTL1; | |
| MPEG1; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | MPEG1 | Macrophage-expressed gene 1 protein | Q2M385 | CHEMBL3414409 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.444E-08 | 4.580E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 6.917E-08 | 1.482E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.948E-07 | 2.652E-04 | ALOX12, CDK1, CSNK2A1, FLT3, HIF1A, IGF1R, KDR, MAPK1, MMP12, PIM1, THPO |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.205E-07 | 2.726E-04 | ALOX12, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD17B1, HSD17B10, HSD17B2, NOX4, TYR |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.778E-07 | 2.792E-04 | AHR, CSNK2A1, HIF1A, KDR |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.264E-07 | 2.961E-04 | ALOX12, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.929E-07 | 4.116E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.073E-06 | 4.869E-04 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.408E-06 | 5.955E-04 | CYP19A1, HSD17B1, HSD17B2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.235E-06 | 8.536E-04 | CA12, CA4, CA7 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.818E-06 | 1.023E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.485E-06 | 1.961E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.614E-06 | 2.501E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 9.382E-06 | 2.619E-03 | AXL, CDK1, CSNK2A1, FLT3 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 9.873E-06 | 2.687E-03 | ALOX12, HIF1A, IGF1R, KDR, MAPK1, MET, NOX4 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.740E-05 | 4.088E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0002376; immune system process | GO:0030097; hemopoiesis | 1.757E-05 | 4.088E-03 | FLT3, HIF1A, KDR, L3MBTL1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.800E-05 | 4.127E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.419E-05 | 7.090E-03 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 4.169E-05 | 8.388E-03 | ACHE, ALOX12, CSNK2A1, CYP19A1, CYP1A1, HSD17B1, HSD17B2 |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 4.491E-05 | 8.810E-03 | ALOX12, ALOX5 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 4.911E-05 | 9.381E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 4.982E-05 | 9.434E-03 | AXL, FLT3, HIF1A, POLB |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.013E-12 | 2.516E-10 | HSD17B1, ALOX5, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.757E-10 | 3.598E-08 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.945E-06 | 1.545E-04 | FLT3, MAPK1, MET, HIF1A |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 7.361E-06 | 1.840E-04 | CSNK2A1, MAPK1, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.246E-05 | 4.679E-04 | KDR, MAPK1, HIF1A, MET, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.248E-05 | 7.586E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.003E-06 | 1.251E-04 | CA12, CA4, CA7 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.233E-04 | 1.927E-03 | FLT3, PIM1, MAPK1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.668E-04 | 2.317E-03 | HSD17B1, ALOX5, HSD17B2, CYP1A2, CYP1A1, ALOX12, TYR, CYP19A1, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.909E-04 | 2.386E-03 | MAPK1, MET, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.371E-04 | 2.681E-03 | MAPK1, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.204E-04 | 4.066E-03 | FLT3, MAPK1, HIF1A, MET, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 3.695E-04 | 3.299E-03 | KDR, MAPK1, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 4.357E-04 | 3.631E-03 | KDR, MAPK1, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.574E-04 | 2.681E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 5.737E-04 | 4.218E-03 | KDR, MAPK1, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 6.114E-04 | 4.246E-03 | CDK1, MAPK1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.627E-04 | 3.299E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.068E-04 | 4.650E-03 | MAPK1, HIF1A, IGF1R |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 1.022E-03 | 6.083E-03 | THPO, FLT3, KDR, MET |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 9.015E-04 | 5.634E-03 | ALOX5, MAPK1, ALOX12 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 1.182E-03 | 6.715E-03 | CDK1, MAPK1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.556E-03 | 8.455E-03 | PIM1, CYP1B1, MAPK1, MET |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CYP19A1; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; ALOX5; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; ALOX5; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; ALOX5; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; HIF1A; MAPK1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MAPK1; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| NA: NA | HIV infections | NA | AHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ALOX5; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; ALOX5; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
